Skip to main content

Lupus

exhibitor.floor.ACR
Bags are packed, ready to go, but wait there’s more abstracts to show. The big news today were the “late breaking” abstracts. This is usually a favorite session of many as this is where the newest…
RT @doctorRBC: Deucravacitinib: TYK2 inhibitor in pts with active SLE
Phase 2, randomized, double blind, placebo-control

Robert B Chao, MD doctorRBC

1 month ago
Deucravacitinib: TYK2 inhibitor in pts with active SLE Phase 2, randomized, double blind, placebo-controlled study Met primary endpoint SRI response across all doses No death, MACE, VTE, systemic infections @RheumNow #EULAR2022 ABST#LB0004 https://t.co/yAM8qUZgee
RT @RichardPAConway: Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE

Richard Conway RichardPAConway

1 month ago
Prof Hoi @alberta_hoi Anti-Sm in SLE. Present in 17%. Assoc severe disease activity, "classic" SLE manifestations, specific serologic and proteomic profile. Argues for Sm+ SLE being a specific subset (or even a "different" disease?) @RheumNow #EULAR2022 POS0774 https://t.co/a5dToAuao9
RT @RichardPAConway: Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabr

Richard Conway RichardPAConway

1 month ago
Li et al. Orelabrutinib in SLE. 60 patient phase 2 RCT. Week 12 SRI(4) 50.0%/61.5%/64.3% in orelabrutinib groups vs 35.7% PBO. @RheumNow #EULAR2022 LB0005 https://t.co/u0UUWKal7n https://t.co/aYFf7Lpx1L
RT @Yuz6Yusof: #LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in

Md Yuzaiful Md Yusof Yuz6Yusof

1 month ago
#LB0005 #EULAR2022 Phase 1B/2A dose-ranging RCT of Orelabrutinib, a BTK-inhibitor showed BTK occupancy in all doses in #lupus. SRI-4 response was higher in all doses vs PBO. Effects were better in SLEDAI=>8. Well tolerated & no major safety. Promising early data @RheumNow https://t.co/vJBLRQgYBP
RT @ericdeinmd: #EULAR2022 LB0005
Orelabrutinib- BTKi- for SLE, PIb/IIa
⭐️Improved SRI-4 and SLEDAI-2K vs PBO, dose

Eric Dein ericdeinmd

1 month ago
#EULAR2022 LB0005 Orelabrutinib- BTKi- for SLE, PIb/IIa ⭐️Improved SRI-4 and SLEDAI-2K vs PBO, dose response for SRI-4 ⭐️Improved proteinuria @Rheumnow https://t.co/bmREhmL7sq
RT @KDAO2011: Another possible Rx for #SLE:
Phase Ib/IIa orelabrutinib (irrevers BTKi) for SLE shows promise. Improvemen

TheDaoIndex KDAO2011

1 month ago
Another possible Rx for #SLE: Phase Ib/IIa orelabrutinib (irrevers BTKi) for SLE shows promise. Improvement in SRI-4, SLEDAI2K, proteinuria, dsDNA, C3/C4; dec in IgG/M/Bcells. Safety: lymphopenia w/ORE #EULAR2022 LB0005 @rheumnow https://t.co/etZ9hMYNfn
×